2024
A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies
Swallow M, Edelson R, Girardi M. A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies. Clinics In Dermatology 2024, 43: 170-176. PMID: 39694197, DOI: 10.1016/j.clindermatol.2024.12.006.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaMycosis fungoidesSubtype of cutaneous T-cell lymphomaPathogenesis of cutaneous T-cell lymphomaNon-Hodgkin's lymphomaEvolving treatment landscapeSezary syndromeHistological variantsTreatment landscapeLymph nodesSchool of MedicineLymphomaYale School of MedicineFungoidesClinical careMalignancyLymphMycosisSyndromeSubtypesPathogenesisDifficult to Treat Depression: Focus on Approach, Algorithms, and Access.
Karp J, Brinton R, Fournier J, Harding L, Jha M, Lenze E, Mathew S, Meltzer-Brody S, Mohr D, Riva-Posse P, Wiechers I, Williams N. Difficult to Treat Depression: Focus on Approach, Algorithms, and Access. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39630090, DOI: 10.4088/jcp.psprmdd2408ah.Peer-Reviewed Original ResearchConceptsTreating depressionSpectrum of clinical severityTreatment of depressionEvolving treatment landscapeDepartment of PsychiatryBurden of depressionOral pharmacotherapyTreatment landscapeAdult patientsClinical severityCommunity health agenciesDepressionIncreased prevalenceHealth care systemPatientsDepression carePsychiatric workforcePsychiatryPatient advocatesCare systemTherapeutic engineeringHealth agenciesTelemedicine platformDo IRemissionTrends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis
Hanin A, Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Wainwright M, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L. Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia 2024, 65: e148-e155. PMID: 38837761, DOI: 10.1111/epi.18014.Peer-Reviewed Original ResearchNew-onset refractory status epilepticusSecond-line immunotherapyKetogenic dietStatus epilepticusDuration of status epilepticusRefractory status epilepticusStatus epilepticus onsetManagement of patientsEvolving treatment landscapeTreatment landscapeImmunotherapyConsensus recommendationsInterim analysisPatientsPatient outcomesAnakinraEpilepticusShort durationMedianORCIDietDaysTocilizumabIncreased use
2023
Moving toward disease modification in polycythemia vera
Bewersdorf J, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal R. Moving toward disease modification in polycythemia vera. Blood 2023, 142: 1859-1870. PMID: 37729609, DOI: 10.1182/blood.2023021503.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaProgression to myelofibrosisPolycythemia veraCytoreductive therapyBCR-ABL1-negative myeloproliferative neoplasmsLow-risk PVLow-risk diseaseHistory of thrombosisHigh-risk diseaseDisease-modifying treatment modalitiesAssociated with higher ratesEvolving treatment landscapeClinically meaningful outcome measuresDisease-related symptomsInterferon alfaMyeloproliferative neoplasmsThromboembolic eventsPatient ageMyeloid leukemiaTreatment modalitiesIFN-a2bTherapeutic phlebotomyActivating mutationsVasomotor symptomsDisease course
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply